Achillion Pharmaceuticals, Inc. (ACHN) Analysts See $-0.14 EPS

October 14, 2018 - By Peter Erickson

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) LogoInvestors sentiment increased to 1.38 in 2018 Q2. Its up 0.43, from 0.95 in 2018Q1. It improved, as 11 investors sold Achillion Pharmaceuticals, Inc. shares while 29 reduced holdings. 16 funds opened positions while 39 raised stakes. 105.68 million shares or 1.67% less from 107.48 million shares in 2018Q1 were reported.
Utd Services Automobile Association holds 148,552 shares. Raymond James & stated it has 63,050 shares. Hightower Advisors Ltd Liability accumulated 0% or 14,398 shares. South Dakota Council holds 0.05% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) for 747,600 shares. Hbk Investments Limited Partnership invested in 42,900 shares or 0% of the stock. Qs Limited Liability Corp has invested 0.01% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Financial Bank Of Mellon Corp invested in 621,676 shares. Moreover, Amer Gp has 0% invested in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). 416,817 were reported by State Bank Of America De. Amalgamated National Bank accumulated 18,270 shares. Stifel Corp stated it has 401,200 shares. Tiaa Cref Inv Management Limited Liability Company holds 0% or 621,860 shares. Sweden-based Rhenman & Prns Asset Ab has invested 0.18% in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Spark Inv Mngmt Limited Liability Company invested 0.03% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN). Manufacturers Life The has invested 0% of its portfolio in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Analysts expect Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) to report $-0.14 EPS on November, 7.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.14 EPS. After having $-0.12 EPS previously, Achillion Pharmaceuticals, Inc.’s analysts see 16.67 % EPS growth. The stock increased 1.62% or $0.05 during the last trading session, reaching $3.13. About 937,123 shares traded. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has declined 11.53% since October 14, 2017 and is downtrending. It has underperformed by 27.15% the S&P500.

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the United States and internationally. The company has market cap of $433.77 million. The Company’s drug candidates for treating chronic hepatitis C virus infection comprise Odalasvir, a NS5A inhibitor, which has completed Phase IIa clinical trials; ACH-3422, a NS5B nucleotide polymerase inhibitor; and Sovaprevir, a NS3 protease inhibitor that has completed Phase II clinical trial. It currently has negative earnings. The firm is also developing ACH-4471, a complement factor D inhibitor, which is in Phase I clinical trial to treat patients with paroxysmal nocturnal hemoglobinuria and C3G, a disease resulting from alternative pathway over-activation; and other factor D inhibitors.

More news for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) were recently published by: Seekingalpha.com, which released: “Ra Pharma’s zilucoplan shows favorable PK profile in renal impairment patients, expanding potential clinical programs” on September 26, 2018. Globenewswire.com‘s article titled: “Achillion to Present at the Leerink Partners Roundtable Series” and published on September 25, 2018 is yet another important article.

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

>